How to Get CagriSema Online in France

Many patients in France are searching for how to obtain new weight-loss treatments like CagriSema online. However, it's important to understand that CagriSema is currently not approved for weight-loss prescription in the EU, including France, and is therefore not offered by Hi-Doctor. Here, we explain what CagriSema actually is, its current regulatory status, and what proven, EU-approved weight-loss medications you CAN get today from an EU-licensed doctor.

What is CagriSema, and why isn't it a normal option yet?

CagriSema is an investigational drug combining two active substances: cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist). This combination aims to reduce appetite and improve metabolic control through multiple pathways. While early clinical trials have shown promising results for weight loss and blood sugar regulation, CagriSema is still in advanced stages of clinical development. It has not yet received marketing authorization from the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for weight management. This means it cannot be legally prescribed or sold in France or any other EU country. Seeking CagriSema from unregulated online sources is extremely risky, as these products may be counterfeit, unsafe, or ineffective, and lack medical oversight.

Proven weight-loss medications available online today

While CagriSema is not yet available, several highly effective and EU-approved weight-loss medications are accessible through prescription today. An EU-licensed doctor can assess your individual health profile to determine the most appropriate treatment.

• Ozempic (semaglutide): Primarily approved for type 2 diabetes, Ozempic also induces significant weight loss and can be prescribed off-label for weight management by a doctor when clinically appropriate.
• Wegovy (semaglutide): This is a higher-dose formulation of semaglutide, specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
• Mounjaro (tirzepatide): A GIP and GLP-1 receptor agonist, Mounjaro is approved for type 2 diabetes and has demonstrated superior weight loss compared to semaglutide in clinical trials. It can be prescribed off-label for weight management.
• Saxenda (liraglutide): An earlier GLP-1 receptor agonist, Saxenda is approved for chronic weight management and is suitable for patients who may not tolerate other options or prefer a daily injection.

How to get a weight-loss prescription online in France

Hi-Doctor offers a straightforward, safe, and legal path to obtaining an EU-approved weight-loss prescription, valid in France and across the EU. Our process ensures medical oversight and compliance with all regulations:

1. Complete a brief online questionnaire: In just 2–3 minutes, you provide essential medical information for the doctor's review.
2. EU-licensed doctor reviews your case: An experienced EU-licensed physician carefully assesses your health profile and medical history to determine if treatment is appropriate for you. If a doctor finds the treatment is not suitable, your €25 consultation fee is refunded automatically.
3. Receive your REMPE prescription in <24 h (if approved): If the doctor approves, you'll receive a REMPE (Spanish standard, valid EU-wide) electronic prescription as a downloadable PDF in your private account and by email.
4. Pick up at any EU pharmacy: Print your prescription or show it on your phone at any pharmacy in France or any other EU country, thanks to cross-border prescription directive 2011/24/EU.

The online consultation fee is a flat 25 €.

Why choose Hi-Doctor over unregulated peptide sellers

When considering weight-loss treatments, safety and legitimacy are paramount. Hi-Doctor provides a secure, regulated alternative to the risks associated with unregulated peptide sellers or 'research chemical' vendors:

• EU-licensed doctors: Your case is reviewed by qualified medical professionals who adhere to EU medical standards.
• Real medications, real pharmacies: We connect you with legitimate, EU-approved medications dispensed by licensed pharmacies, ensuring product quality and safety.
• Auditable and compliant: All communications and records are stored in your private, RGPD-compliant account, ensuring data protection and traceability.
• Trusted by thousands: With over 50,000 patients served and a 4.8 Trustpilot rating, Hi-Doctor is a reliable platform for online medical consultations.
• Money-back guarantee: If a doctor determines treatment is not appropriate, your consultation fee is automatically refunded.

We believe in providing medically honest care and transparent access to approved treatments, unlike grey-market vendors who operate without medical oversight or quality control.

Frequently asked questions

Is CagriSema legal to buy online in France?

No, CagriSema is not legally approved for commercial sale or prescription in France or the EU. Any online offers claiming to sell it are likely counterfeit or illegal.

When will CagriSema be available by prescription?

The exact timeline for CagriSema's approval is uncertain. It is still undergoing clinical trials and regulatory review, which can take several years. You can register your interest at hi-doctor.ai to be notified if and when new treatments become available through our service.

What's the closest approved alternative to CagriSema?

While no exact equivalent exists, medications like Mounjaro (tirzepatide), which is a dual GLP-1 and GIP agonist, offer a similar multi-pathway approach to weight loss and are currently available by prescription.

How much does an online weight-loss consultation cost?

A consultation with an EU-licensed doctor through Hi-Doctor costs a flat fee of 25 €. This fee is refunded if the doctor determines treatment is not appropriate for you.

Can I use a Hi-Doctor prescription at any pharmacy?

Yes, the REMPE electronic prescription provided by Hi-Doctor is valid at any pharmacy in France and across all EU countries, thanks to the cross-border prescription directive 2011/24/EU.